Viyash Scientific Q2 Results 2026: PAT ₹85 Cr (+331.9% YoY)
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹988Cr
- +133% YoY
- +4.4% QoQ
- Net profit
- ₹85Cr
- +331.9% YoY
- +6.8% QoQ
- Margin
- 16.7%
- +3.6 pp YoY
- −2.1 pp QoQ
Guidance rank: #74 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Viyash Scientific Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY.
As stated in Viyash Scientific Ltd's Q2 FY27 investor presentation · published 13 Nov 2026. Reported figures, not investment advice.
Based on Viyash Scientific Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8). EBITDA for Q2 FY27: ₹2,077 million, up 10.3% YoY (Page 8).
From Viyash Scientific Ltd's Q2 FY27 earnings-call transcript · updated 13 Nov 2026.
How did Viyash Scientific's revenue grow in the September 2026 quarter?
- Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8)
- Q2 FY27 reported sales: ₹9,879 million, up 16% YoY (Page 10)
- H1 FY27 revenue: ₹19,343 million, up 17.8% YoY (Page 5)
- Sustained sales growth shown with consistent EBITDA expansion (Page 7)
2 more points from Viyash Scientific Ltd's call on revenue
Create a free account to keep reading this call
What happened to Viyash Scientific's margins in Q2 FY27?
EBITDA for Q2 FY27: ₹2,077 million, up 10.3% YoY (Page 8)
Locked: what Viyash Scientific Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Viyash Scientific planning?
- New manufacturing block at Viyash-IV, Nalgonda:
- Adds 128 KL API capacity.
- Approved; all necessary approvals received.
- Purpose: To meet rising demand and support backward integration.
- New dedicated companion animal facility, Ambernath:
- Capex initiated for new tablet facility.
2 more points from Viyash Scientific Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Viyash Scientific raising money or cutting debt?
Net Debt figures are provided: ₹861 Mn in Q1 FY27 and ₹261 Mn reported at the time of the presentation.
Locked: what Viyash Scientific Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Viyash Scientific's order book?
See what Viyash Scientific Ltd said on order book & pipeline — free account, 30 seconds.
Viyash Scientific Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the table below.
Viyash Scientific Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 988 | 424 | +133% | 946 | +4.4% |
| Operating profit (EBITDA) | 165 | 56 | +196.2% | 178 | -7.5% |
| Operating margin | 16.7% | 13.1% | +3.6 pp | 18.8% | -2.1 pp |
| Profit before tax | 118 | 27 | +333.3% | 112 | +4.7% |
| Net profit (PAT) | 85 | 20 | +331.9% | 79 | +6.8% |
| EPS (₹) | 1.74 | 0.59 | +194.9% | 1.51 | +15.2% |
Source: Viyash Scientific Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Viyash Scientific's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Innova Captab (Q2 FY27)
Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take
- Natco Pharma (Q2 FY27)
EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline) . Key investor presentation takeaways from Natco Pharma Ltd's Q2 FY27 invest
- Vineet Laborator (Q2 FY27)
Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27
- Balaxi Pharma (Q2 FY27)
34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Viyash Scientific Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Viyash Scientific Ltd Q2 FY27 results?
Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8). EBITDA for Q2 FY27: ₹2,077 million, up 10.3% YoY (Page 8).
What is Viyash Scientific Ltd share price analysis?
Viyash Scientific Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹11,289 Cr. Investors should review the full earnings analysis for detailed insights.
Is Viyash Scientific Ltd planning capital expenditure?
New manufacturing block at Viyash-IV, Nalgonda:.
Keep Viyash Scientific Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.